Peroxisome Proliferator-Activated Receptor agonists and antagonists: an updated patent review (2020–2023)

Barbara De Filippis,Arianna Granese,Alessandra Ammazzalorso
DOI: https://doi.org/10.1080/13543776.2024.2332661
2024-03-22
Expert Opinion on Therapeutic Patents
Abstract:Introduction The search for novel compounds targeting Peroxisome Proliferator-Activated Receptors (PPARs) is currently ongoing, starting from the previous successfully identification of selective, dual or pan agonists. In last years, researchers' efforts are mainly paid to the discovery of PPARγ and δ modulators, both agonists and antagonists, selective or with a dual-multitarget profile. Some of these compounds are currently under clinical trials for the treatment of primary biliary cirrhosis, nonalcoholic fatty liver disease, hepatic, and renal diseases.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?